Biologic response modifier agents as first-line treatment for patients with rheumatoid arthritis: a review of the clinical efficacy, cost-effectiveness and guidelines
CADTH
Record ID 32014000202
English
Authors' recommendations:
Randomized controlled trials of biologic agents used as first line treatment of patients with rheumatoid arthritis, who have not previously received methotrexate or other disease modifying antirheumatic therapies, have shown benefit in terms of clinical response and radiographic progression in the short-term (up to one year), compared to methotrexate monotherapy. The cost-effectiveness of first line biologic therapy exceeded commonly reported willingness to pay thresholds in six of eight economic evaluations conducted in countries other than Canada. Evidence based guidelines were inconsistent, with one recommending against first line biologic therapy, and three advocating for biologic use in a subset of patients with poor prognostic factors or high disease activity.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.cadth.ca/media/pdf/htis/apr-2013/RC0434%20Biologics%20RA%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antirheumatic Agents
- Tumor Necrosis Factor-alpha
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.